|
WINNIPEG, Manitoba – January 8, 2010 – Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, announces that in connection with its recently announced partnership with Inverness Medical Innovations (“Inverness”), Miraculins and Mount Sinai Hospital (“MSH”) have agreed to certain amendments to the royalty and fee structure (the “Amendments”) of their License Agreement originally announced on October 15, 2008.
Read More
|
|
WINNIPEG, Manitoba – June 25th, 2009– Miraculins Inc. (TSX-V:MOM), a Canadian company focused on developing and commercializing medical diagnostic tests for unmet clinical needs, is pleased to announce the finalization of a Research Collaboration Agreement with Diagnostic Technologies Ltd. (DTL), an Israel based developer of diagnostic kits and devices for monitoring pregnancy disorders. In addition, Miraculins also announces the execution of a Cooperation and Project Funding Agreement with DTL and CIIRDF (Canada-Israel Industrial Research and Development Foundation).
Read More
|
|
WINNIPEG, Manitoba – April 27, 2009 - Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, today announces a non-brokered private placement offering (the “Offering”) of up to 5,000,000 units (“Units”) at a price of $0.05 per Unit for gross proceeds of up to $250,000. Each Unit will be comprised of one common share of the Company (a “Share”) and one Share purchase warrant (a “Warrant”). Each Warrant will entitle the holder to purchase one Share at a price of $0.10 per Share for a period of 24 months from the date the Warrant is issued.
Read More
|
|
WINNIPEG, Manitoba – February 12th, 2009 – Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, is pleased to announce that Dr. Isabella Caniggia has joined its Scientific Advisory Board. Dr. Caniggia is an internationally recognized preeclampsia researcher and physician at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in Toronto.
Read More
|
|
WINNIPEG, Manitoba – February 10th, 2009 – Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, is pleased to announce results which demonstrate that PSP94 in urine can be used to improve the performance of free over total (F/T) PSA ratio in detecting aggressive prostate cancer. The improvement offered by PSP94 is believed to be a novel discovery.
Read More
|
|
|